



**GMMM** Interface Prescribing  
Subgroup



**Agenda**

**10<sup>th</sup> September, 1pm-3pm**

**Dawes Family Practice, 83 Spotland Road, Rochdale OL12 6RX**

[Declarations of Interest](#) (new declarations only)

Apologies:

	<b>ENC</b>
<b>1) Draft Minutes of 13<sup>th</sup> August 2015</b>	Item 1
<b>2) Matters Arising</b> <ul style="list-style-type: none"> <li>a) RAG List Recommendations from May meeting – awaiting GMMM approval</li> <li>b) RAG List Recommendations from June meeting – awaiting GMMM approval</li> <li>c) RAG List Recommendations from July meeting (melatonin &amp; antipsychotics in LD – comments received)</li> <li>d) RAG List Recommendations from August meeting – currently out for comment until 1<sup>st</sup> October 2015.</li> <li>e) Inclusion of Grey/DNP List drugs on RAG list</li> <li>f) Melatonin dose in paediatric melatonin SCP</li> <li>g) Colobreathe</li> <li>h) Naltrexone for opioid dependence</li> <li>i) CCG Funding arrangements for SCPs</li> </ul>	Item 2c(i) Item 2c(ii) Item 2c(iii)
<b>3) Nalmefene SCP – 2<sup>nd</sup> draft</b>	Item 3
<b>4) Drugs requiring a review of RAG status</b> <ul style="list-style-type: none"> <li>• Tapentadol</li> <li>• Azathioprine for Interstitial Lung Disease</li> </ul>	
<b>5) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</b> <ul style="list-style-type: none"> <li>• Naloxegol for opioid induced constipation</li> <li>• Clobazam for epilepsy</li> <li>• Clonazepam for epilepsy</li> </ul>	
<b>6) Share Care Protocols awaiting approval at Sept 2015 GMMM</b> <ul style="list-style-type: none"> <li>• Mercaptopurine and Azathioprine for Inflammatory bowel disease</li> <li>• Azathioprine for the treatment of chronic inflammatory bowel disease (unlicensed use) in paediatric patients</li> <li>• SSRIs in children and adolescents for OCD &amp; BDD</li> <li>• SSRIs in children and adolescents for depression</li> <li>• SSRIs in children and adolescents for anxiety</li> </ul>	

<ul style="list-style-type: none"> <li>• Antipsychotics for schizophrenia in children &amp; adolescents</li> <li>• Antipsychotics for OCD in children &amp; adolescents</li> <li>• Antipsychotics for Bipolar in children &amp; adolescents</li> </ul>	
<b>7) Share Care Protocols for approval – final versions for GMMMG</b> <ul style="list-style-type: none"> <li>• Ethinylestradiol for pubertal induction</li> <li>• Ciclosporin for paediatric nephrotic syndrome</li> </ul>	Item 7a Item 7b Item 7c
<b>8) Shared Care Protocols – drafts to go out to CCG/Trusts for comment</b> <ul style="list-style-type: none"> <li>• Riluzole</li> <li>• Adult ADHD</li> <li>• Melatonin in LD aged 18-55 where behavioural interventions have failed and on-going treatment in CAMHS graduates where clinically indicated.</li> <li>• Antipsychotics for challenging behaviours and learning disabilities</li> <li>• Lithium in adults</li> </ul>	Item 8a Item 8b Item 8c Item 8d Item 8e
<b>9) SCPs to archive as of September 2015</b>	Item 9
<b>10) Addition of GM Strategic Lead Commissioner for Mental Health to IPS membership – <i>group is asked to consider this addition to the membership</i></b>	
<b>11) Updates from other groups</b>	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMG (verbal)	
<b>12) AOB</b> <ul style="list-style-type: none"> <li>• Rheumatology DMARD SCPs – extending review date</li> <li>• Retigabine RAG status</li> </ul>	
<b>Date of Next Meeting: 8<sup>th</sup> October 2015, 1pm-3pm, Croft Shifa Health Centre, Belfield Road, Rochdale OL16 2UP</b>	